Recent cases of GMP violations by Korean pharmaceutical companies have served as an opportunity to guard against risks throughout the industry. In addition, there are opinions that it should be improved in the wake of this incident.

Until now, actual changes in standards for GMP have been sluggish according to global level. Only a few companies aiming to expand overseas have voluntarily attempted to improve.

Looking at the recent cases, most small and medium-sized companies have been commissioned to produce pharmaceutical drugs to the domestic market, but even large companies, which are consignment companies, cannot avoid responsibility. The consignee lacked quality control, and the trustee